Press releases

On 22 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2017.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00...

02/13/2018 - 09:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) will present new evidence at the upcoming 11th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), in Madrid, Spain, 7-9 February 2018. These data mark the company´s long-term commitment to elevate haemophilia...

02/07/2018 - 12:30

The Republic of Ireland has become the first country in Europe where every person with haemophilia will have access to the newest generation of haemophilia treatments, extended half-life therapies, under new supply contracts signed between the HSE (Health Services Executive) and Sobi.

A new...

02/07/2018 - 09:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the FDA has issued a Study may proceed letter for the first study in humans, thereby accepting the investigational new drug (IND) application for the drug candidate SOBI003. In addition, SOBI003 was granted Fast Track status by the FDA....

01/23/2018 - 09:00

Post-hoc longitudinal analysis from B-LONG and B-YOND studies shows patients who progressed to individualised prophylactic dosing intervals of 14 days or longer maintained low annualised bleeding rates.

Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) and Bioverativ Inc. (NASDAQ: BIVVV) today...

12/11/2017 - 16:02

Press contacts

Subscribe to our press releases and financial reports